Conexeu Sciences Inc. - 8-K Filing
Conexeu Sciences Inc. filed an 8-K on July 7, 2026, announcing completion of its P.R.O.O.F preclinical study (Performance and Regeneration Outcomes of Flowable Collagen) for the CXU™ platform. The 12-month study met tissue restoration objectives in small-volume facial models (cheek), large-volume subcutaneous applications (up to 200cc-equivalent), and injectability/volumizing benchmarks required for aesthetic injectables. Results will support a predicate-based 510(k) submission in wound care, planned for Q1 2027. (Items: 7.01 Regulation FD Disclosure On July 7, 2026, Conexeu Sciences Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Description 99)
Tickers: $CNXU